← Eichor
Study identifier: NCT04764357 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors

Condition: Alopecia  ·  Sponsor: St. Jude Children's Research Hospital

PhaseNA
Planned participants40
Who can joinAll sexes, 7 Years to no upper limit
Healthy volunteersNo

About this study

This study is being done to see if the Paxman scalp cooling device can prevent hair loss in pediatric patients receiving chemotherapy for non-cancerous conditions or solid tumors. Primary Objective * To assess the safety and feasibility of the use of a scalp cooling device in pediatric and young adult patients receiving chemotherapy for non-malignant conditions and solid tumors. Exploratory Objectives * To assess the incidence and intensity of chemotherapy induced hair loss in patients receiving chemotherapy for non-malignant conditions and solid tumors who have used a scalp cooling device.

This description comes directly from the study's public registry record.

Talk to the study team

Deena Levine, MD  ·  888-226-4343  ·  referralinfo@stjude.org

Always discuss trial participation with your own doctor first.

Locations (1)

St. Jude Children's Research HospitalMemphis, Tennessee, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04764357